- Latest version of AdaptCHECK™ software validated for interoperability with Accela
- Delivers speed and efficiency gains necessary for confident independent verification of adaptive treatments without disrupting workflow
MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts and clinical partners for interoperability with the company's new radiotherapy system, Accela. Unveiled at the annual ASTRO conference, Accela is the first software-driven delivery system engineered for NeoArc (Dynamic Modulated Arc Therapy, DMAT), a new treatment technique that accelerates how radiation therapy is planned, delivered, and adapted.
AdaptCHECK, built on the SunCHECK® Patient workflow, is Sun Nuclear's quality assurance (QA) software for adaptive radiation therapy. It delivers fast, patient-specific dose verification -- covering secondary dose calculations, plan-of-the-day recalculations, and log-file-based treatment monitoring -- so treatments stay safe and on track without slowing down care.
“For adaptive radiotherapy to realize its full potential, it must be fast and efficient," said Margaret Johns, President, Sun Nuclear – Radiation Therapy QA. “AdaptCHECK delivers the speed and efficiency needed for verification of adapted NeoArc plans, without disrupting workflow.”
Adaptive radiation therapy represents one of the most significant advances in modern cancer treatment, allowing clinicians to adjust a patient’s treatment plan, accounting for daily anatomical changes such as tumor shrinkage, weight loss, or organ movement. By tailoring each session to the patient's current anatomy, adaptive workflows have the potential to improve treatment precision, reduce dose to healthy tissue, and ultimately enhance clinical outcomes. As more clinics adopt this approach and the need for independent dose verification increases, tools like AdaptCHECK become essential.
Added Johns: “Sun Nuclear has always strived to empower the field of radiation therapy through efficient, independent QA solutions that enhance clinical confidence and patient safety, while easing new treatment technology adoption. With AdaptCHECK and with more Sun Nuclear solutions, we are very pleased to support the game-changing release of Accela with NeoArc.”
“The Accela radiotherapy system and NeoArc represent an important milestone for Siemens Healthineers and will empower cancer institutions to treat a broader range of patients, more precisely, and in significantly less time,” said Sasa Mutic, President of Radiation Oncology Solutions at Varian. “Sun Nuclear has demonstrated fast, secondary dose calculation for NeoArc treatment on Accela.”
For those attending ASTRO 2026 in Boston, please visit the Sun Nuclear booth #915 for demonstrations on AdaptCHECK, Daily QA™ 4 Pro, SunSCAN™ 3D, and additional solutions to support Accela with NeoArc adoption and implementation.
About Sun Nuclear
Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion, providing innovative solutions for Radiation Therapy and Diagnostic Imaging. More than 6,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Learn more: sunnuclear.com.
About Siemens Healthineers
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.
Sun Nuclear, AdaptCHECK, SunCHECK, Daily QA 4 Pro, and SunSCAN 3D are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries. Sun Nuclear Corporation is not affiliated with or sponsored by Varian Medical Systems, Inc. Accela and NeoArc are products of Varian Medical Systems, Inc., a Siemens Healthineers company. 510(k) pending. Not available for sale in any market and no guarantee of commercialization or feature availability.
Contacts
For media inquiries:
Erin Schesny, media@mirion.com
For investor inquiries:
Eric Linn, ir@mirion.com
